Company Analysis - WuXi AppTec reported strong Q3 2025 financial results, with revenue increasing by 15.3% year-on-year, and adjusted Non-IFRS net profit rising significantly by 42.0% [2] - The company raised its full-year revenue guidance to a range of RMB 43.5 billion to RMB 44 billion, up from the previous guidance of RMB 42.5 billion to RMB 43.5 billion, indicating robust business execution despite macro uncertainties [2] - As of Q3 2025, the company's backlog for its small molecule D&M business reached RMB 59.88 billion, a year-on-year increase of 41.2%, highlighting its role as a key growth driver [6] Market Performance - The Hang Seng Index closed at 26,434, up 1.05% for the day and 31.77% year-to-date, reflecting positive market sentiment [3] - The Chinese stock market saw gains, with sectors such as materials, information technology, and consumer discretionary leading the way, while telecommunications, finance, and energy lagged [5] - The U.S. stock market also experienced upward momentum, with the S&P 500 and Nasdaq rising by 1.23% and 1.86% respectively, driven by improved risk appetite following U.S.-China trade negotiations [5] Industry Insights - The chemical segment of WuXi AppTec showed signs of recovery, with drug discovery services experiencing a slight revenue decline of 2.0% year-on-year, but the decline is narrowing [7] - The company is witnessing early signs of demand recovery in the industry, attributed to improvements in the macro environment, including a rebound in the domestic capital market and favorable global business development transactions [7] - The management anticipates that the revenue growth from the small molecule D&M segment will significantly impact overall revenue growth, as it constitutes 46% of total revenue in 2024 [6]

Macro Commentary - The US September CPI year-on-year growth rate continues to rise slightly but is below market expectations, with core CPI showing a month-on-month slowdown [2] - The Federal Reserve is expected to focus more on employment risks, with a potential interest rate cut in October or December, targeting a year-end federal funds rate of 3.75%-4% [2] - The Chinese stock market saw gains, with sectors like materials, consumer discretionary, and information technology leading, while utilities, consumer staples, and real estate lagged [4] Industry Commentary - The MSCI China Healthcare Index has risen 58.6% since the beginning of 2025, outperforming the MSCI China Index by 24.2%, indicating a recovery in the pharmaceutical sector [5] - The CXO industry is expected to see performance recovery in the second half of 2025 due to a resurgence in demand for innovative drug development and a rebound in capital market financing [5] - The report highlights the importance of clinical progress for authorized innovative drug pipelines overseas as a catalyst for stock price increases [7] Company Commentary - Great Wall Motors reported a slight decline in gross margin in Q3 2025, with a 3.6% increase in average selling price, but net profit fell 50% to 2.3 billion yuan due to delays in tax refunds [9] - The company maintains a sales forecast of 1.35 million units for 2025, with expectations for Q4 sales to reach 430,000 units, reflecting an 11% year-on-year growth [9] - Xiaomi is expected to report a strong Q3 2025 performance, with a projected 60% year-on-year increase in adjusted net profit, driven by robust electric vehicle sales [14] - Weibo anticipates a 5% decline in total revenue for Q3 2025, primarily due to weaker advertising demand from certain industries [15]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [2][33]. Core Insights - The MSCI China Healthcare Index has increased by 58.6% from early 2025, outperforming the MSCI China Index by 24.2%. However, there has been a recent pullback of 10% in the healthcare sector, presenting a buying opportunity [1]. - The report highlights a recovery in the demand for domestic innovative drug research and development, driven by a resurgence in capital market financing and an increase in overseas clinical trials for authorized innovative drugs [1]. - The CXO industry is expected to see performance recovery in the second half of 2025, aided by the recent interest rate cuts in the U.S. [1]. - The report emphasizes the importance of monitoring the clinical progress of authorized innovative drug pipelines overseas, as this could serve as a catalyst for stock price increases [4]. Summary by Sections Industry Overview - The report discusses the recent clinical data released at the ESMO conference, focusing on several key drugs and their performance in clinical trials, such as SKB264 and ivonescimab, which show promising results in treating specific types of cancer [4]. - It notes that while business development (BD) activities for innovative drugs are ongoing, stock prices have not reflected this positively, primarily due to valuation concerns [4]. Company Ratings and Valuations - The report provides a detailed valuation table for several companies, including: - **Sangamo Therapeutics (1530 HK)**: Market cap of $8.76 billion, target price of $37.58, with a 34% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $932.7 million, target price of $48.28, with a 62% upside potential [2]. - **Giant Biologics (2367 HK)**: Market cap of $5.74 billion, target price of $58.35, with a 40% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10.87 billion, target price of $74.00, with a 5% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $16.80 billion, target price of $9.40, with a 35% upside potential [2]. - **Innovent Biologics (1801 HK)**: Market cap of $18.94 billion, target price of $110.62, with a 29% upside potential [2].

Inflation Trends - September CPI year-on-year growth rose to 3%, slightly below market expectations[2] - Core CPI month-on-month growth decreased from 0.35% to 0.23%, also below expectations[5] - Energy prices saw a month-on-month increase from 0.7% to 1.5%, with gasoline prices rebounding from 1.9% to 4.1%[5] Federal Reserve Outlook - The Federal Reserve is expected to lower interest rates once more by the end of the year, targeting a federal funds rate of 3.75%-4%[2] - Further rate cuts are anticipated next year, potentially bringing the rate down to 3.25%-3.5%[2] Housing and Services Impact - Rent inflation significantly declined, with the month-on-month growth rate dropping from 0.36% to 0.15%, the lowest since early 2021[5] - Other service inflation remains high, with travel services like lodging and airfare showing strong demand[5] Future Projections - October CPI month-on-month growth is expected to decrease to 0.2%, maintaining a year-on-year growth of 3%[5] - The potential for significant deviations in CPI data due to reduced sample collection is noted, increasing uncertainty around future rate cuts[2]

Macro Commentary - The core objective of China's "14th Five-Year Plan" (2026-2030) emphasizes high-quality development, shifting focus from GDP growth to technological self-reliance and economic transformation [2][4] - Key strategic industries highlighted include artificial intelligence, semiconductors, advanced robotics, green energy, aerospace, and industrial software [2] - The plan aims to rebalance the economy towards consumption-driven growth, with increased investment in social services such as healthcare and elder care, benefiting sectors like consumer staples and healthcare [2][4] Market Performance - The Hang Seng Index closed at 25,968, up 0.72% year-to-date performance is 29.45% [2] - The Shanghai Composite Index closed at 3,922, with a year-to-date increase of 17.03% [2] - U.S. markets showed positive performance, with the Dow Jones up 0.27% and the S&P 500 up 0.49% [2][4] Company Analysis - **Giant Bio (2367 HK)**: The approval of its first injectable aesthetic product marks the beginning of a new growth phase for the company. The product is aimed at facial dermal filling to correct dynamic wrinkles [5][6] - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic market, which is expected to drive growth [5] - **Thermo Fisher (TMO US)**: Reported a strong 3Q25 performance with a revenue increase of 5.0% year-on-year and an adjusted EPS growth of 9.7%. The company raised its full-year guidance based on robust performance [6][7] - The demand from pharma and biotech clients is showing positive signs, with revenue growth driven by bioproduction and analytical instruments [7][8] - The company is expected to benefit from the trend of pharmaceutical companies establishing manufacturing facilities in the U.S., which will reflect in its performance by 2027-2028 [9]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 58.35, down from a previous target of HKD 71.30, indicating a potential upside of 41.6% from the current price of HKD 41.20 [2][4]. Core Insights - The approval of the first injectable aesthetic product, recombinant type I α1 collagen, marks the beginning of a second growth curve for the company, expanding its product matrix in the aesthetic medicine sector [1][8]. - The Chinese aesthetic injection market is projected to reach RMB 147 billion by 2027, with the collagen injection segment expected to grow to RMB 16.8 billion, highlighting significant growth potential [8]. - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic medicine market, which is expected to drive growth from the new injectable products [8]. Financial Summary - Sales revenue is projected to grow from RMB 3,524 million in FY23A to RMB 8,715 million in FY27E, with a CAGR of approximately 17.7% [3][13]. - Net profit is expected to increase from RMB 1,451.8 million in FY23A to RMB 2,820.5 million in FY27E, reflecting a growth rate of 13.5% [3][13]. - The company’s net debt ratio is projected to increase from (57.2%) in FY23A to (73.4%) in FY27E, indicating a shift towards higher leverage [3][13]. Product Development - The company has two additional injectable collagen products in the approval stage, which are expected to enhance its aesthetic product portfolio and address various anti-aging needs [8][9]. - The newly approved injectable product is designed for facial dermal filling to correct dynamic wrinkles, positioning the company competitively in the market [9]. Market Position - The company has established a comprehensive product matrix that includes injectable products, post-surgery recovery dressings, and functional skincare, allowing it to capture a broader market share [1][8]. - The competitive landscape includes several other approved products, but the company’s strong distribution channels and brand recognition are expected to provide a competitive edge [8][9].

Market Overview - The global stock markets experienced a decline, with the Hang Seng Index falling by 0.94% and the Hang Seng Tech Index dropping by 1.41%. Year-to-date, the Hang Seng Index is up 28.52% [1][2] - In the A-share market, sectors such as non-ferrous metals and electrical equipment saw significant declines, while oil, banking, and real estate sectors showed the largest gains [3] Hong Kong Market Insights - The Hong Kong market is considering easing conditions for private equity funds to open to retail clients, which may enhance its position as an international asset and wealth management center [3] - Southbound capital saw a net inflow of HKD 10.018 billion, with notable net purchases in the Tracker Fund of Hong Kong, CNOOC, and SMIC, while stocks like Hua Hong Semiconductor, Xiaomi, and Alibaba faced net selling [3] Company Analysis: Meituan - For Q3 2025, Meituan is expected to achieve revenue of RMB 97.8 billion, reflecting a year-on-year growth of 4.6%. However, the adjusted net loss is projected to be RMB 16.6 billion, exceeding market expectations due to intense competition in the food delivery sector [4] - The target price for Meituan has been adjusted from HKD 164.0 to HKD 154.4, maintaining a "Buy" rating [4] Company Analysis: Innovent Biologics - Innovent Biologics has established a global strategic collaboration with Takeda Pharmaceutical for several key oncology assets, including IBI363 and IBI343, aimed at enhancing its global footprint and strengthening Takeda's oncology pipeline [5][6] - The collaboration is valued at up to USD 1.14 billion, including an upfront payment of USD 1 billion and potential milestone payments [5] - Innovent aims to transition into a comprehensive biopharmaceutical company with global R&D capabilities, targeting to advance at least five assets into global Phase III multi-regional clinical trials by 2030 [5] Clinical Development Updates - IBI363 and IBI343 are entering global late-stage development, with IBI363 showing competitive progression-free survival in various cancer types. Global Phase III trials are planned for both assets [6][7] - The strategic partnership with Takeda is expected to introduce new immuno-oncology assets to Takeda's portfolio, enhancing its revenue potential in the oncology sector [5][6]

Report Summary 1. Report Industry Investment Rating No information provided in the report regarding the industry investment rating. 2. Core Viewpoints - The report provides a comprehensive update on the fixed - income market, including bond price movements, new issues, and macro - economic news. It maintains a buy recommendation on the FAEACO 12.814 Perp bond, which has gained about 20 pts in the past two weeks [2]. - SoftBank Group's new bond issues are analyzed, with estimated fair values for SOFTBK 61s and SOFTBK 65s at around 7.6% and 8.4% respectively [4][8][9]. 3. Section - by - Section Summaries Trading Desk Comments - Yesterday, the TW lifers/BBLTB sub curve/HYUELE curve/PETMK curve tightened by 1 - 3 bps. There were two - way flows on JP/KR/AU front - end FRNs from PBs [2]. - Japanese insurance hybrids and AT1s edged 0.1 pt firmer with light flows, while Yankee AT1s opened cautiously in London. BNP papers recovered after a previous plunge [2]. - Chinese IG benchmarks tightened by 1 - 2 bps. In Greater China higher - beta space, NWDEVL 28 - 31s were up 0.6 - 1.5 pts, but NWDEVL Perps were down 0.3 - 1.3 pts. FAEACO 12.814 Perp gained 0.4 pt [2]. - In Chinese properties, VNKRLE 27 - 29s decreased by 0.4 - 0.6 pt after Moody's downgrade. YUZHOU 27 lost 0.7 pt. In Southeast Asia, VLLPM 27 - 29s led the space and rose 3.2 - 4.4 pts [2]. - In LGFV space, there were mixed, light two - way flows. RMs and AMs were topping up IG USD and AAA - guaranteed issues, and flows on higher - yielding papers were sporadic [3]. Morning Update - This morning, the new ASBBNK 4.155 30 tightened 1 bp from initial issuance at T + 60, and ASBBNK Float 30 tightened 10 bps from RO at SOFR+90. The new GSCCOR 4.25 30 tightened 1 bp from pricing at T + 77 [4]. - The new GEZHOU 4.25 Perp traded up to 0.1 pt higher with light flows. SOFTBKs were unchanged, and LGELECs were unchanged after S&P revised the outlook of LG Electronics to positive from stable [4]. Top Performers and Underperformers - Top performers included VLLPM 7 1/4 07/20/27 (price 69.2, change 4.4) and NWDEVL 4 1/2 05/19/30 (price 72.7, change 1.5). Top underperformers included NWDEVL 5 1/4 PERP (price 48.8, change - 1.3) and YUZHOU 7 06/30/27 (price 12.0, change - 0.7) [5]. Macro News Recap - On Tuesday, the S&P was flat (+0.00%), the Dow rose 0.47%, and the Nasdaq fell 0.16%. UST yields were lower, with 2/5/10/30 - year yields at 3.45%/3.56%/3.98%/4.55% [7]. Desk Analyst Comments on SoftBank - SoftBank Group proposes to issue 35.5NC5.5 and 40NC10 Reg S USD subordinated bonds (S&P: B+) and 37NC7 EUR subordinated bonds for general corporate purposes [8]. - The fair value of the new SOFTBK 61 (first call Apr'31) is estimated at around 7.6% vs IPT at 7.875% - 8%, and for the new SOFTBK 65 (first call Oct'35) at around 8.4% vs IPT at 8.5% - 8.625% [9]. - The bonds have step - up mechanisms, and will receive 50% equity credit from S&P and JCR until the first reset date. SoftBank has a track record of calling its bonds on the first call date [10]. - In Jun'25, SoftBank's investment portfolio was valued at about USD269.6 bn, with 76% in listed shares (about USD205 bn). It held cash of about USD25.3 bn and standalone net debts of about USD45.9 bn, with an LTV ratio of 17.0% [11][12]. - While it has completed refinancing for the current fiscal year, there is a medium - term refinancing requirement in 2028 - 31, but it has access to diverse funding channels [12]. Offshore Asia New Issues - Priced new issues include ASB Bank (USD500/300 mn, 5 - year, 4.155%/SOFR+90), China Energy Overseas Investment (USD100/100 mn, 3 - year/PerpNC5, 3.8%/4.25%), GS Caltex Corporation (USD300 mn, 5 - year, 4.25%), and Republic of Kazakhstan (USD1500 mn, 5 - year, 4.412%) [16]. - Pipeline new issues include Avation Plc, China Three Gorges Corporation, Softbank Group, and The Republic of Korea with various tenors and coupon rates [17]. News and Market Color - Yesterday, there were 158 onshore credit bonds issued with an amount of RMB156 bn. Month - to - date, 910 credit bonds were issued with a total amount of RMB889 bn, a 31.1% yoy increase [18]. - S&P revised the outlook of LG Electronics to positive from stable, and the Republic of Indonesia is looking to price 5 - year/10 - year dim sum bonds tomorrow [18]. - Other corporate news includes S&P revising the outlook of Japfa Comfeed to stable from negative, NWD denying LME on perps, San Miguel obtaining a USD1.5 bn syndicated loan, Sun Hung Kai Properties announcing a USD10 bn debt instruments issuance programme, and Woodside Energy's 9M25 oil and gas output rising 5% yoy [25].

Global Market Overview - The Hang Seng Index closed at 26,028, up 0.65% for the day and 29.75% year-to-date [1] - The Shanghai Composite Index rose by 1.36% to 3,916, with a year-to-date increase of 16.84% [1] - The Shenzhen Component Index increased by 1.76% to 2,463, showing a year-to-date rise of 25.83% [1] - The US markets showed mixed results, with the Dow Jones up 0.47% and the S&P 500 unchanged, while the Nasdaq fell by 0.16% [1] Sector Performance - The Hang Seng Financial Index rose by 1.06% to 45,270, with a year-to-date increase of 28.84% [2] - The Hang Seng Industrial and Commercial Index increased by 0.52% to 14,826, reflecting a year-to-date rise of 31.79% [2] - The Hang Seng Real Estate Index slightly decreased by 0.05% to 18,358, with a year-to-date increase of 23.10% [2] Capital Flows and Stock Performance - Southbound capital recorded a net inflow of HKD 1.17 billion, with notable net purchases in Pop Mart, Xiaomi, and Hua Hong Semiconductor [3] - Pop Mart's Q3 revenue is expected to grow by 245%-250% year-on-year, with overseas revenue increasing by 365%-370% [3] - A-shares in hardware equipment, semiconductors, and industrial trade showed strong gains, while coal, telecommunications, and household goods lagged [3] Economic and Policy Developments - The Chinese Commerce Minister held talks with EU officials to address semiconductor issues, emphasizing the importance of maintaining global supply chain stability [3] - Japan's new Prime Minister, Kishida, may influence the Bank of Japan to delay interest rate hikes, with market expectations for an October rate increase dropping to 25% [3] US Market Insights - US stock performance was mixed, with consumer discretionary, industrials, and healthcare sectors leading gains, while utilities, communication services, and materials declined [3] - Strong Q3 earnings reports have boosted investor sentiment, with 86% of companies exceeding earnings expectations [3] - Notable stock movements included significant gains for Coca-Cola and 3M, while Netflix faced a decline due to lower-than-expected earnings [3] Commodity and Currency Trends - US Treasury yields fell, while the dollar index continued to rise [3] - Gold and silver prices dropped amid reduced geopolitical tensions, although speculative long positions in these metals have increased [3] - Oil prices rebounded as the White House announced plans to purchase 1 million barrels for the Strategic Petroleum Reserve [3]

Group 1: Market Overview - The Hang Seng Index closed at 25,859, up 2.42% for the day and 28.91% year-to-date [1] - The US stock market saw the Dow Jones increase by 1.12%, while the S&P 500 and Nasdaq rose by 1.07% and 1.37% respectively [1] - The Nikkei 225 index in Japan surged by 3.37%, reaching a historical high [3] Group 2: Sector Performance - In the Hong Kong market, the Hang Seng Financial sector rose by 1.92%, while the Hang Seng Industrial sector increased by 2.79% [2] - The Hang Seng Technology sector outperformed with a 3.00% increase, reflecting strong performance in selected consumer and technology stocks [3] - The Australian stock market saw a 0.41% increase in the ASX 200 index, indicating a stable performance [1] Group 3: Economic Insights - China's economic growth is expected to slow down, with a projected GDP growth rate of 5% for the year and a potential drop to 4.6% by Q4 2025 [4] - The People's Bank of China is anticipated to implement further monetary easing, including a possible 50 basis points reserve requirement ratio cut and a 10 basis points interest rate reduction [4] - The implementation of anti-involution policies may temporarily hinder economic growth but is expected to promote long-term economic rebalancing and alleviate deflationary pressures [4] Group 4: Company Analysis - Yancoal Australia (3668 HK) reported a 9% decrease in production for Q3 2025 due to adverse weather conditions, while sales increased by 3% [5] - The average coal price for Yancoal Australia fell by 18% year-on-year, leading to a projected revenue of approximately AUD 1.48 billion, a 17% decline compared to the previous year [5] - Despite the short-term challenges, Yancoal Australia maintains a "Buy" rating due to its strong balance sheet and stable dividend policy [5]